Previous 10 | Next 10 |
This has not been the year of marijuana stocks. Although that's not too surprising, as equity markets have been southbound, the industry has substantially lagged the broader market. Thankfully, there is hope for cannabis investors. While estimates vary, analysts have predicted that the pot indust...
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab PR Newswire Follows positive top-line clinical data readout from HERIZON-BTC-01 pivotal trial in biliary tract cancers DUBLIN and VANCOUVER, BC , ...
Jazz Pharmaceuticals ( NASDAQ: JAZZ ) traded higher in the pre-market Friday after Goldman Sachs upgraded the Ireland-based biopharma to Buy from Neutral, citing a favorable outlook for its operating margin performance. The upgrade comes weeks after Avadel Pharmaceuticals ( AVDL )...
Summary Avadel's LUMRYZ in treatment of cataplexy in adults with narcolepsy received tentative FDA approval, temporarily blocked by a patent owned by Jazz Pharmaceuticals. The situation creates a David vs. Goliath match-up of great importance for both companies. Jazz is taking the f...
Summary Lumyrz overhang now removed with competitor ordered to delist patent from FDA's Orange Book. The treatment has potential to create a remedial breakthrough in narcolepsy. We rate AVDL a buy now with the overhang removed, with far more clarity on the route to full FDA approval...
The Daily Hit is a recap of cannabis business news for Dec. 5, 2022. ON THE SITE Biden Signs Historic Marijuana Research Bill, Lawmakers Push Additional Measures After months of policy debates and trading barbs on Capitol Hill, a U.S. president has finally sent through the first p...
Ireland-based Jazz Pharmaceuticals (Nasdaq: JAZZ) announced that its anti-epileptic over-the-counter cannabis drug, Epidiolex , has been found to be effective “across age groups,” not just young children, according to a survey of caregivers presented recently at a gather...
Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies PR Newswire Real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) Car...
Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting PR Newswire Data from six abstracts to be presented, including new long-term Phase 3 results and two real-world analyses of U.S...
It's been a mostly down year for cannabis stocks. Declining profits for some multi-state operators (MSOs) have soured many investors on the sector, with the ETFMG Alternative Harvest ETF and the AdvisorShares Pure Cannabis ETF down roughly 46% and 58%, respectively, so far this year...
News, Short Squeeze, Breakout and More Instantly...
Jazz Pharmaceuticals plc Company Name:
JAZZ Stock Symbol:
NASDAQ Market:
Jazz Pharmaceuticals plc Website:
Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance PR Newswire – 15% year-over-year revenue increase from combined key growth drivers: Xywav ® , Epidiolex ® and Rylaze ® – – O...
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting PR Newswire Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN , July 25, 20...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals In celebration of Pride Month , we were joined by Celia Sandhya Daniels (she/they) who led an insightful discussion aimed at educating, raising awareness and calling for unders...